Developer docs
API playgroundTry for free, no card

Search company profiles

RetinaLyze System

Full company profile

uuid000frxp

Namestring
RetinaLyze System
Websiteurl
retinalyze.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

RetinaLyze System develops AI-assisted ophthalmic screening software designed to detect eye diseases from retinal imagery. The company's product screens for five clinical conditions — glaucoma, diabetic retinopathy, cataract, age-related macular degeneration (AMD), and retinopathy of prematurity (ROP) — positioning it as a multi-condition screening platform rather than a single-disease algorithm. The software is delivered to eye-care professionals, opticians, and general practitioners, and is exposed via an application programming interface (API) for integration into third-party clinical workflows and electronic health record systems, indicating a platform rather than purely standalone-portal distribution model.

The company was founded in 2013 and is headquartered in Hellerup, Denmark. Leadership comprises founder and CEO Barbara Anthonsen, co-founder and CCO Ganesh Ram, and co-founder, CTO and Technical Manager Morten Guldager Moller. Headcount is reported in the 11–50 range, placing it in the small-SMB category. The company operates as a private entity and, per available records, has not raised external venture funding — its documented funding history shows a 2014 round with $0 raised, consistent with a bootstrapped capital structure.

The business model centers on selling or licensing AI screening software to healthcare professionals and clinics, though pricing structure (per-scan fee, subscription, or capital license) is not publicly disclosed. No named customer accounts, distribution partnerships, or revenue figures are available in the input, limiting visibility into commercial traction. Geographic reach beyond Denmark is not documented, and the company competes in a healthcare AI segment that includes better-capitalized entrants with disclosed regulatory clearances, making capital-light bootstrapping a notable strategic constraint.

Short descriptiontext

RetinaLyze System develops AI-assisted ophthalmic screening software for eye-care providers, covering glaucoma, diabetic retinopathy, cataract, AMD, and ROP. Founded in 2013 in Hellerup, Denmark, the bootstrapped company serves healthcare professionals via a cloud platform with API integration.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHerlev, Denmark
HQ citystring
Herlev
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
AI ophthalmic screening, retinal disease detection, eye care diagnostics, diabetic retinopathy screening, ophthalmic AI software
Industry3 codes
PRIMARYHLAHAJAB
Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAN
Ocular Imaging & Diagnostic Testing Centers
SECONDARYHLAKAKAE
Retina & Vitreous Specialists
NAICS code1 code
  • Custom Computer Programming Services541511
SIC code2 codes
  • Optical Instruments & Lenses3827
  • Services-Computer Programming Services7371
Product category
AI Ophthalmology Diagnostics
Social media profiles3 records
Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

RetinaLyze System develops artificial intelligence-powered software that screens eyes for ophthalmic diseases including glaucoma, diabetic retinopathy, cataract, age-related macular degeneration (AMD), and retinopathy of prematurity (ROP). The software provides AI-assisted diagnostic support to eye care providers and healthcare professionals for early detection of these conditions.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1RetinaLyze AI Ophthalmic Screening Software
CategoryAI Ophthalmology Diagnostics
Description

AI-assisted diagnostic software that screens retinal images for eye diseases including glaucoma, diabetic retinopathy, cataract, age-related macular degeneration (AMD), and retinopathy of prematurity (ROP). Built for eye care providers and healthcare professionals who need automated early detection support.

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pioneer in autonomous AI diagnostics for diabetic retinopathy (IDx-DR), the first FDA-cleared AI diagnostic in any specialty. Directly comparable to RetinaLyze's DR screening use case and software-based delivery model.

TypeDirect peer
Description

Provides ophthalmic diagnostic devices including retinal imaging and glaucoma screening tools. Overlaps with RetinaLyze's target conditions and serves optometrists/ophthalmologists.

TypeDirect peer
Description

AI retinal screening provider with FDA clearance for DR detection from fundus images. Closely aligned product offering to RetinaLyze's ophthalmic AI screening positioning.

TypeDirect peer
Description

Finnish company offering handheld fundus cameras plus AI-based screening software for DR and other retinal diseases. Comparable combination of imaging device plus AI diagnostics for eye care providers.

TypeDirect peer
Description

Developer of EyeArt, an FDA-cleared AI system for autonomous DR screening. Operates in the same AI retinal screening category with similar eye care provider customer base.

TypeBroad incumbent
Description

Major ophthalmic device manufacturer offering fundus cameras, OCT, and integrated AI screening software. A broad incumbent that competes with RetinaLyze at the integrated imaging-plus-AI layer.

TypeEmerging player
Description

AI image analysis provider with ophthalmic screening products including retinal image analysis. Emerging competitor with European base similar to RetinaLyze, focusing on AI-driven diagnostics.

TypeEmerging player
Description

AI-driven vision assistance technology company. While its primary product is wearable low-vision assistance, it represents a broader AI-vision thematic peer relevant to RetinaLyze's category.

TypeRegional player
Description

German-headquartered manufacturer of ophthalmic diagnostic instruments including direct and indirect ophthalmoscopes. Comparable in serving European eye care professionals with diagnostic tools, though primarily hardware-focused.

TypeBroad incumbent
Description

Global ophthalmic equipment leader offering retinal imaging, OCT, and AI-assisted diagnostics. Sets the standard for clinical ophthalmic workflows where AI software like RetinaLyze must integrate.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RetinaLyze System

AI Ophthalmology Diagnosticsretinalyze.com

RetinaLyze System develops AI-assisted ophthalmic screening software for eye-care providers, covering glaucoma, diabetic retinopathy, cataract, AMD, and ROP. Founded in 2013 in Hellerup, Denmark, the bootstrapped company serves healthcare professionals via a cloud platform with API integration.

What RetinaLyze System does

RetinaLyze System develops AI-assisted ophthalmic screening software designed to detect eye diseases from retinal imagery. The company's product screens for five clinical conditions — glaucoma, diabetic retinopathy, cataract, age-related macular degeneration (AMD), and retinopathy of prematurity (ROP) — positioning it as a multi-condition screening platform rather than a single-disease algorithm. The software is delivered to eye-care professionals, opticians, and general practitioners, and is exposed via an application programming interface (API) for integration into third-party clinical workflows and electronic health record systems, indicating a platform rather than purely standalone-portal distribution model.

The company was founded in 2013 and is headquartered in Hellerup, Denmark. Leadership comprises founder and CEO Barbara Anthonsen, co-founder and CCO Ganesh Ram, and co-founder, CTO and Technical Manager Morten Guldager Moller. Headcount is reported in the 11–50 range, placing it in the small-SMB category. The company operates as a private entity and, per available records, has not raised external venture funding — its documented funding history shows a 2014 round with $0 raised, consistent with a bootstrapped capital structure.

The business model centers on selling or licensing AI screening software to healthcare professionals and clinics, though pricing structure (per-scan fee, subscription, or capital license) is not publicly disclosed. No named customer accounts, distribution partnerships, or revenue figures are available in the input, limiting visibility into commercial traction. Geographic reach beyond Denmark is not documented, and the company competes in a healthcare AI segment that includes better-capitalized entrants with disclosed regulatory clearances, making capital-light bootstrapping a notable strategic constraint.

RetinaLyze System firmographics

Firmographics
Name
RetinaLyze System
Website
https://retinalyze.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
1–10 employees
Short description
RetinaLyze System develops AI-assisted ophthalmic screening software for eye-care providers, covering glaucoma, diabetic retinopathy, cataract, AMD, and ROP. Founded in 2013 in Hellerup, Denmark, the bootstrapped company serves healthcare professionals via a cloud platform with API integration.
Ownership category
akta.pro rank

RetinaLyze System industry classification

Industry
Product category
AI Ophthalmology Diagnostics
NAICS
Custom Computer Programming Services (541511)
SIC
Optical Instruments & Lenses (3827), Services-Computer Programming Services (7371)
akta.pro industry
PRIMARYHLAHAJAB
Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAN
Ocular Imaging & Diagnostic Testing Centers
SECONDARYHLAKAKAE
Retina & Vitreous Specialists

Keywords

  • AI ophthalmic screening
  • Retinal disease detection
  • Eye care diagnostics
  • Diabetic retinopathy screening
  • Ophthalmic AI software

Where RetinaLyze System is headquartered

Location

Headquarters

HQ city
Herlev
HQ country
Denmark
HQ region
Europe

Markets served

RetinaLyze System business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

RetinaLyze System product offering

Product offering

Core offering

RetinaLyze System develops artificial intelligence-powered software that screens eyes for ophthalmic diseases including glaucoma, diabetic retinopathy, cataract, age-related macular degeneration (AMD), and retinopathy of prematurity (ROP). The software provides AI-assisted diagnostic support to eye care providers and healthcare professionals for early detection of these conditions.

Differentiator

Problem solved

Functional benefit

Products and services

  • RetinaLyze AI Ophthalmic Screening Software AI-assisted diagnostic software that screens retinal images for eye diseases including glaucoma, diabetic retinopathy, cataract, age-related macular degeneration (AMD), and retinopathy of prematurity (ROP). Built for eye care providers and healthcare professionals who need automated early detection support.

Companies that use RetinaLyze System

Customer profile

Segments1 record

Ideal customer profiles1 record

RetinaLyze System technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

RetinaLyze System partnerships and signals

Strategic signal

Recent moves2 records

Expansion highlights2 records

RetinaLyze System competitors and assessment

Company assessment

Direct peers

  • Digital Diagnostics: Pioneer in autonomous AI diagnostics for diabetic retinopathy (IDx-DR), the first FDA-cleared AI diagnostic in any specialty. Directly comparable to RetinaLyze's DR screening use case and software-based delivery model.
  • iCare (Revenio Group): Provides ophthalmic diagnostic devices including retinal imaging and glaucoma screening tools. Overlaps with RetinaLyze's target conditions and serves optometrists/ophthalmologists.
  • AEYE Health: AI retinal screening provider with FDA clearance for DR detection from fundus images. Closely aligned product offering to RetinaLyze's ophthalmic AI screening positioning.
  • Optomed: Finnish company offering handheld fundus cameras plus AI-based screening software for DR and other retinal diseases. Comparable combination of imaging device plus AI diagnostics for eye care providers.
  • Eyenuk: Developer of EyeArt, an FDA-cleared AI system for autonomous DR screening. Operates in the same AI retinal screening category with similar eye care provider customer base.

Broad incumbents

  • Topcon Healthcare: Major ophthalmic device manufacturer offering fundus cameras, OCT, and integrated AI screening software. A broad incumbent that competes with RetinaLyze at the integrated imaging-plus-AI layer.
  • ZEISS Medical Technology: Global ophthalmic equipment leader offering retinal imaging, OCT, and AI-assisted diagnostics. Sets the standard for clinical ophthalmic workflows where AI software like RetinaLyze must integrate.

Emerging players

  • Thirona Retina: AI image analysis provider with ophthalmic screening products including retinal image analysis. Emerging competitor with European base similar to RetinaLyze, focusing on AI-driven diagnostics.
  • OrCam Technologies: AI-driven vision assistance technology company. While its primary product is wearable low-vision assistance, it represents a broader AI-vision thematic peer relevant to RetinaLyze's category.

Regional players

  • HEINE Optotechnik: German-headquartered manufacturer of ophthalmic diagnostic instruments including direct and indirect ophthalmoscopes. Comparable in serving European eye care professionals with diagnostic tools, though primarily hardware-focused.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

RetinaLyze System social profiles

Digital presence

RetinaLyze System financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RetinaLyze System leadership team

Management profile

Number of profiles

Profiles3 records

RetinaLyze System funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RetinaLyze System M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RetinaLyze System

What does RetinaLyze System do?

RetinaLyze System develops artificial intelligence-powered software that screens eyes for ophthalmic diseases including glaucoma, diabetic retinopathy, cataract, age-related macular degeneration (AMD), and retinopathy of prematurity (ROP). The software provides AI-assisted diagnostic support to eye care providers and healthcare professionals for early detection of these conditions.

Is RetinaLyze System a public or private company?

RetinaLyze System is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was RetinaLyze System founded?

RetinaLyze System was founded in 2013. It employs 1 to 10 people.

Where is RetinaLyze System based?

RetinaLyze System is headquartered in Herlev, Denmark, in the Europe region.

Who are RetinaLyze System's main competitors?

Direct peers on record are Digital Diagnostics, iCare (Revenio Group), AEYE Health, Optomed and Eyenuk. Broad incumbents are Topcon Healthcare and ZEISS Medical Technology. Emerging players are Thirona Retina and OrCam Technologies. HEINE Optotechnik is listed as a regional player.

Does RetinaLyze System have an API?

No public API is recorded for RetinaLyze System.

What industry is RetinaLyze System in?

RetinaLyze System's product category is AI Ophthalmology Diagnostics. Its primary akta.pro industry code is HLAHAJAB, Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography), with a secondary code of HLAKAKAN, Ocular Imaging & Diagnostic Testing Centers. Its NAICS code is 541511 and its SIC code is 3827.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals